Skip to main content
Journal cover image

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Publication ,  Journal Article
Patel, HD; Puligandla, M; Shuch, BM; Leibovich, BC; Kapoor, A; Master, VA; Drake, CG; Heng, DY; Lara, PN; Choueiri, TK; Maskens, D; Singer, EA ...
Published in: Future Oncol
May 2019

Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic RCC. There is emerging data across other solid tumors of the potential efficacy of neoadjuvant PD-1 blockade, and preclinical evidence supporting a neoadjuvant over adjuvant approach. PROSPER RCC is a Phase III, randomized trial evaluating whether perioperative nivolumab increases recurrence-free survival in patients with high-risk RCC undergoing nephrectomy. The neoadjuvant component, intended to prime the immune system for enhanced efficacy, distinguishes PROSPER from other purely adjuvant studies and permits highly clinically relevant translational studies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

May 2019

Volume

15

Issue

15

Start / End Page

1683 / 1695

Location

England

Related Subject Headings

  • Treatment Outcome
  • Perioperative Care
  • Oncology & Carcinogenesis
  • Nephrectomy
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Molecular Targeted Therapy
  • Kidney Neoplasms
  • Humans
  • Disease Susceptibility
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, H. D., Puligandla, M., Shuch, B. M., Leibovich, B. C., Kapoor, A., Master, V. A., … Allaf, M. E. (2019). The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol, 15(15), 1683–1695. https://doi.org/10.2217/fon-2018-0951
Patel, Hiten D., Maneka Puligandla, Brian M. Shuch, Bradley C. Leibovich, Anil Kapoor, Viraj A. Master, Charles G. Drake, et al. “The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Future Oncol 15, no. 15 (May 2019): 1683–95. https://doi.org/10.2217/fon-2018-0951.
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, et al. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May;15(15):1683–95.
Patel, Hiten D., et al. “The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Future Oncol, vol. 15, no. 15, May 2019, pp. 1683–95. Pubmed, doi:10.2217/fon-2018-0951.
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May;15(15):1683–1695.
Journal cover image

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

May 2019

Volume

15

Issue

15

Start / End Page

1683 / 1695

Location

England

Related Subject Headings

  • Treatment Outcome
  • Perioperative Care
  • Oncology & Carcinogenesis
  • Nephrectomy
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Molecular Targeted Therapy
  • Kidney Neoplasms
  • Humans
  • Disease Susceptibility